A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Clinical Trial

Official title:
A Phase Ib Multicenter, Open-Label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Status Recruiting

Clinical Trial Summary

This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non-Hodgkin lymphoma (r/r B-NHL).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Clinical Trial Details

NCT number	NCT05421663
Study type	Interventional
Source	Janssen Research & Development, LLC
Contact	Study Contact, M.D.
Phone	844-434-4210
Email	Participate-In-This-Study@its.jnj.com
Status	Recruiting
Phase	Phase 1
Start date	August 12, 2022
Completion date	October 28, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05784441` - A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)	Phase 1
Recruiting	`NCT06173518` - A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)	Phase 1
Recruiting	`NCT02981745` - Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia	Phase 1/Phase 2